- Home
- BBD vs ONC Comparison
BBD vs ONC Comparison
Compare BBD & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBD
- ONC
- Stock Information
- Founded
- BBD 1943
- ONC 2010
- Country
- BBD Brazil
- ONC Switzerland
- Employees
- BBD 83285
- ONC N/A
- Industry
- BBD Major Banks
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- BBD Finance
- ONC Health Care
- Exchange
- BBD Nasdaq
- ONC Nasdaq
- Market Cap
- BBD 32.7B
- ONC 26.9B
- IPO Year
- BBD N/A
- ONC N/A
- Fundamental
- Price
- BBD $3.10
- ONC $245.49
- Analyst Decision
- BBD Strong Buy
- ONC Strong Buy
- Analyst Count
- BBD 4
- ONC 9
- Target Price
- BBD $2.55
- ONC $325.56
- AVG Volume (30 Days)
- BBD 39.2M
- ONC 367.8K
- Earning Date
- BBD 08-04-2025
- ONC 08-06-2025
- Dividend Yield
- BBD 4.92%
- ONC N/A
- EPS Growth
- BBD 44.93
- ONC N/A
- EPS
- BBD 0.31
- ONC N/A
- Revenue
- BBD $14,585,863,742.00
- ONC $4,175,868,000.00
- Revenue This Year
- BBD $68.75
- ONC $869.15
- Revenue Next Year
- BBD $8.99
- ONC $19.07
- P/E Ratio
- BBD $9.30
- ONC N/A
- Revenue Growth
- BBD 23.20
- ONC 51.16
- 52 Week Low
- BBD $1.84
- ONC $142.00
- 52 Week High
- BBD $3.13
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- BBD 65.75
- ONC N/A
- Support Level
- BBD $2.99
- ONC N/A
- Resistance Level
- BBD $3.13
- ONC N/A
- Average True Range (ATR)
- BBD 0.06
- ONC 0.00
- MACD
- BBD -0.01
- ONC 0.00
- Stochastic Oscillator
- BBD 85.00
- ONC 0.00
About BBD Banco Bradesco Sa
Banco Bradesco is Brazil's second-largest private bank, with about 15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation—a private nonprofit institution focused on education. Banking provides roughly 70% of profits, while the insurance segment contributes the remaining 30%. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.